The startup develops sterile injectable products and ophthalmic solutions within an FDA-compliant pharmaceutical facility, initially based in the US and expanding internationally. It provides healthcare professionals with essential antipsychotic and paralytic medications, addressing the critical need for reliable sterile drug manufacturing.
Funding
$580K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
The pharmaceutical industry faces persistent shortages of sterile injectable medications and ophthalmic solutions, hindering healthcare providers' ability to deliver timely and effective treatment. Traditional manufacturing models can be slow and inflexible, struggling to adapt to fluctuating demands and emerging healthcare crises.
Solution
Dawah Pharmaceuticals addresses critical drug shortages by marketing and manufacturing FDA-approved sterile injectable and ophthalmic medicines, including generic alternatives. The company leverages strategic partnerships with top-tier Contract Manufacturing Organizations (CMOs) to ensure a reliable supply of essential medications. By outsourcing production, Dawah Pharmaceuticals focuses on efficient, high-quality drug manufacturing without the constraints of traditional facilities, accelerating timelines and maintaining flexibility. Their portfolio includes a range of therapies across various dosage forms and parenteral therapeutic categories, including generics and 505(b)(2) drugs, with a focus on addressing global healthcare challenges.
Target Audience
Dawah Pharmaceuticals primarily serves healthcare professionals and institutions requiring reliable access to sterile injectable medications and ophthalmic solutions, including hospitals, clinics, and pharmacies.
Features
- Portfolio of FDA-approved sterile injectable and ophthalmic drugs
- Strategic partnerships with global CMOs for efficient manufacturing
- Focus on addressing critical shortages in essential medicines
- Specialization in generic alternatives and 505(b)(2) drugs
- Pipeline includes antipsychotics, paralytics, antibiotics, oncology drugs, antifungals, anti-inflammatory agents, and antihistamines
- Offer intravenous acetaminophen for effective pain and fever control
- Offer critical care solutions, including dopamine and electrolytes for emergency and intensive care applications